Royalty negotiations for novel carbon-capture technology
A major ASX-listed resources company was negotiating a licence for its IP relating to a novel carbon capture technology.
Capability: IP Audit
Valuing a clinical-stage biotech asset to support exit planning
A mid-cap ASX-listed biotech had completed Phase I clinical trials and was preparing a global roadshow to explore acquisition or licensing opportunities.
Aligning JV ownership with the economic value of contributed IP
A US-domiciled multinational mining company was negotiating a joint venture with a small-cap Australian miner to develop a new metals processing technology.